Scientific deep-dive
Mazdutide vs Dulaglutide in Type 2 Diabetes: The Nature Trials
In the phase 3 DREAMS-2 trial, mazdutide beat dulaglutide 1.5 mg on HbA1c and weight at 28 weeks in Chinese adults. Here is what the gap means, why the figures vary, and what the trials leave open on higher dulaglutide doses and heart outcomes.
In the phase 3 DREAMS-2 trial, mazdutide outperformed dulaglutide 1.5 mg on both blood sugar and weight at 28 weeks: the HbA1c difference was −0.24% with mazdutide 4 mg and −0.30% with 6 mg, and the weight difference was −3.78% and −5.76%[1]. The weight gap is the larger finding of the two. The result comes from 731 Chinese adults, and it was measured against a dulaglutide dose below the 4.5 mg maximum on the US label[8], so it does not settle how mazdutide compares with dulaglutide at its top dose.
About this article
This page covers mazdutide as a diabetes drug: the two phase 3 trials published together in Nature and the earlier phase 2 work. For the obesity trials and the drug’s mechanism, see our mazdutide weight-loss evidence review. Details of the Nature trials come from the papers’ abstracts, the company release and a meta-analysis that extracted trial data.
What DREAMS-2 tested
DREAMS-2 randomized 731 adults with type 2 diabetes, 1:1:1, to mazdutide 4 mg, mazdutide 6 mg or dulaglutide 1.5 mg for 28 weeks, all on top of background oral diabetes drugs[1]. A later meta-analysis extracted the baseline data: mean HbA1c of about 8.2%, BMI of 27.6 to 28.1 and diabetes duration of 5.1 to 5.7 years across arms. About 26% of participants took metformin plus an SGLT2 inhibitor or a sulfonylurea[4]. These were people with established diabetes, not new diagnoses.
Both mazdutide doses met the non-inferiority and superiority tests on HbA1c (P = 0.0032 for 4 mg, P = 0.0003 for 6 mg), and both were superior on weight (P < 0.0001)[1]. Eight of the authors are Innovent Biologics employees, and two more consult for the company[1]. A meta-analysis notes that all the head-to-head trials came from one sponsor’s development program[4].
Two sets of DREAMS-2 numbers
Readers will find different figures for this trial. Innovent’s September 2025 approval release gives within-arm changes and explicitly labels them the efficacy estimand, which estimates the drug’s effect if taken as intended[7]. Those figures appear in the table below. The Nature abstract gives between-group differences and names no estimand[1].
| Outcome | Mazdutide 4 mg | Mazdutide 6 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| HbA1c change from baseline | −1.69% | −1.73% | −1.38% |
| Reached HbA1c below 7% | 71.2% | 74.2% | 62.1% |
| Body weight change from baseline | −7.31% | −9.24% | −2.86% |
| HbA1c below 7% and at least 5% weight loss | 50.1% | 64.3% | 19.4% |
Subtracting within the release’s figures gives gaps of about 0.31 and 0.35 points on HbA1c, and 4.45 and 6.38 points on weight[7]. Those are wider than the differences in the Nature abstract, which suggests the two sets may come from different analyses. The abstract names no estimand that would confirm it, so treat them as separate sets and don’t combine them. The peer-reviewed differences in the opening paragraph are the more conservative figures.
DREAMS-1: the placebo trial, in a different population
DREAMS-1 asked a separate question. It enrolled 320 adults on diet and exercise alone, with mean HbA1c of 8.24%, BMI of 28.2 and diabetes duration of just 1.9 years[2]. At week 24, HbA1c changed by −1.57% on mazdutide 4 mg and −2.15% on 6 mg, versus −0.14% on placebo. Weight changed by −5.61% and −7.81%, versus −1.26%[2]. Innovent’s release gives the same figures and labels them the efficacy estimand[7].
A 24-week extension on mazdutide followed, but the abstract reports no extension results[2]. The 2.15% drop is numerically larger than the DREAMS-2 changes reported by the company. That cross-trial gap can’t be credited to the drug alone: DREAMS-1 participants had much newer diabetes, took no background drugs, and were followed for a different length of time[2].
The phase 2 trial did not establish HbA1c superiority
The earlier phase 2 trial is a useful check on the headline. In all, 250 participants received mazdutide 3, 4.5 or 6 mg, open-label dulaglutide 1.5 mg, or placebo for 20 weeks. HbA1c differences versus dulaglutide ranged from −0.06% to −0.32% across mazdutide doses, and of the 4.5 mg and 6 mg doses the authors wrote that “superiority was not established”[3]. Weight ranged from −4.12% to −7.11% on mazdutide, against −2.69% on dulaglutide, and the 4.5 mg and 6 mg doses were significantly better[3]. That trial was smaller and shorter than DREAMS-2, and its dulaglutide arm was not blinded. The pattern still matches: a wide weight gap and a narrow glucose gap.
| Trial | Participants | Arms and length | HbA1c | Weight |
|---|---|---|---|---|
| DREAMS-2 (Guo, Nature); difference vs dulaglutide; no estimand named in abstract | 731 on background oral drugs | Mazdutide 4 mg, 6 mg, dulaglutide 1.5 mg; 28 weeks | −0.24% (4 mg), −0.30% (6 mg) | −3.78% (4 mg), −5.76% (6 mg) |
| DREAMS-1 (Zhu, Nature); change from baseline; efficacy estimand per company | 320 on diet and exercise alone | Mazdutide 4 mg, 6 mg, placebo; 24 weeks | −1.57%, −2.15%, placebo −0.14% | −5.61%, −7.81%, placebo −1.26% |
| Phase 2 (Zhang, Diabetes Care); change from baseline; mixed model | 250 on diet and exercise, or metformin | Mazdutide 3, 4.5, 6 mg, dulaglutide 1.5 mg, placebo; 20 weeks | −1.41% to −1.67%; dulaglutide −1.35%; placebo 0.03% | −4.12% to −7.11%; dulaglutide −2.69%; placebo −1.38% |
Rows differ in comparison, timepoint and analysis, so they can’t be read across as a ranking. Sources: DREAMS-2[1], DREAMS-1[2] and phase 2[3].
What pooling the trials adds
A 2026 meta-analysis pooled the three mazdutide-versus-dulaglutide trials: DREAMS-2, the phase 2 trial and a very small phase 1b study. It found a mean HbA1c difference of −0.25% (95% CI −0.38 to −0.12) with no heterogeneity, and a weight difference of −2.97 kg (95% CI −4.14 to −1.80) with substantial heterogeneity (I² = 74%)[4]. The authors graded HbA1c and the 5% and 10% weight-loss thresholds as high certainty but the weight change itself, in kilograms and percent, as low certainty because of that heterogeneity, and they still called the conclusions preliminary because of the few trials, a single sponsor, a single country and short follow-up[4]. A broader 2026 meta-analysis of nine trials, mostly in Chinese adults, reached a compatible view and asked for longer multi-ethnic studies[5].
Side effects: more diarrhea and appetite loss
Diarrhea, nausea and vomiting were the most common adverse events in DREAMS-2, and gastrointestinal events were more frequent on mazdutide than on dulaglutide[1]. The abstract gives no arm-level rates. The pooled analysis supplies relative odds: diarrhea OR 2.43 (95% CI 1.74 to 3.40) and decreased appetite OR 1.90 (1.37 to 2.63), both significant[4]. Nausea (OR 1.48, 0.88 to 2.48) and vomiting (OR 1.48, 0.87 to 2.53) were numerically higher but not significant. Hypoglycemia (OR 1.75, 0.88 to 3.48), serious adverse events (OR 0.60, 0.34 to 1.05) and discontinuation for adverse events (OR 0.59, 0.15 to 2.24) also showed no significant difference[4]. Those wide intervals leave room for real differences in either direction, and the authors caution that hypoglycemia was not defined the same way across trials[4].
What these trials can't tell you
Dulaglutide at its top dose. All three trials used 1.5 mg as the only dulaglutide dose[4]. The Trulicity label, revised in March 2026, states: “Maximum recommended dosage is 4.5 mg injected subcutaneously once weekly”[8]. In AWARD-11, a separate trial in metformin-treated adults with a mean BMI of 34.2, dulaglutide 4.5 mg beat 1.5 mg at 36 weeks by −0.24% on HbA1c and −1.6 kg on weight, using the treatment-regimen estimand[6]. That is a different population and analysis from DREAMS-2, so it only shows that the comparator dose matters. No trial we found randomized mazdutide against dulaglutide 4.5 mg. For what higher doses do for weight, see our Trulicity weight-loss review.
Heart and kidney outcomes. None of the pooled trials reported cardiovascular or renal outcomes, which the meta-analysis authors call a major limitation[4]. Dulaglutide already has a US indication to reduce major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors[8]. For someone with heart disease, a better weight number does not answer that gap.
Other populations and other drugs. The dulaglutide comparisons were all run in China[4]. The separate DREAMS-3 trial compared mazdutide 6 mg with semaglutide 1 mg in 349 Chinese adults with type 2 diabetes and obesity[10]. Innovent reported that 48.0% on mazdutide and 21.0% on semaglutide reached HbA1c below 7.0% with at least 10% weight loss at week 32, a company-announced result from an open-label trial[11]. A US phase 2 trial funded by Eli Lilly enrolled adults without type 2 diabetes, so it doesn’t fill the gap for US patients with diabetes[12].
Regulatory status and what to raise with a prescriber
China approved mazdutide for weight management in June 2025 and for glycemic control in adults with type 2 diabetes in September 2025[9]. It had no FDA approval when this article was written in November 2026, so dulaglutide and mazdutide are not a choice US patients can make at a pharmacy counter. Our guide to mazdutide’s China approval covers access in more detail. Questions worth bringing to a prescriber:
- If you take dulaglutide 1.5 mg and your HbA1c or weight has stalled, is a higher labeled dose or a different approved drug appropriate? The label allows stepwise increases up to 4.5 mg[8].
- If you have heart or kidney disease, which drugs have outcome data for your situation? The mazdutide comparisons did not report those endpoints[4].
- If you take a sulfonylurea or insulin alongside any GLP-1-based drug, how should glucose monitoring change? Hypoglycemia data for mazdutide remain imprecise[4].
Frequently Asked Questions
References
- 1.Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, et al.; DREAMS-2 investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026. PMID: 41407860.
- 2.Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026. PMID: 41407859.
- 3.Zhang B, Cheng Z, Chen J, Zhang X, Liu D, Jiang H, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. 2024. PMID: 37943529.
- 4.Hassan M, Hussain M, Khan S, Azam MT, Shahid ZUA, Hannan A, et al. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2026. PMID: 42897592.
- 5.Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Khalil I, Hasan M, et al. Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42410325.
- 6.Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021. PMID: 33397768.
- 7.Innovent Biologics. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes (press release, September 19, 2025). BioSpace. 2025. https://www.biospace.com/press-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes
- 8.Eli Lilly and Company. Trulicity (dulaglutide) injection: prescribing information (revised March 2026). DailyMed, US National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
- 9.Shirley M. Mazdutide: First Approval. Drugs. 2025. PMID: 41028652.
- 10.Luo Y, Jiang H, Shi B, Cai H, Wang H, Li S, et al. Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemp Clin Trials. 2026. PMID: 41260459.
- 11.Innovent Biologics. Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-Head Phase 3 Clinical Trial DREAMS-3 (press release, October 26, 2025). PR Newswire. 2025. https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html
- 12.Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026. PMID: 42628555.
Related research
GLORY-2: How Much Weight Did Mazdutide 9 mg Produce?
In the phase 3 GLORY-2 trial, mazdutide 9 mg produced a mean weight change of −16.65% at 60 weeks versus −1.50% on placebo in Chinese adults with obesity. Here is why earlier reports said 18.55% or 20.1%, and how often vomiting and nausea occurred.
7 min read
Mazdutide (IBI362): GLP-1/Glucagon Dual Agonist Weight-Loss Evidence
Mazdutide is a GLP-1/glucagon dual agonist approved in China in 2025 for weight management (not FDA-approved). What the phase 3 GLORY-1 trial showed: -14% body weight at 48 weeks on 6 mg, how it compares to semaglutide and tirzepatide, and what its approval means for US patients.
9 min read
Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows
In the phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg cut liver fat by at least 30% in 68.5% of adults at week 48, versus 28.6% on placebo. What that means, what the biopsy data add, and what the trial cannot show about scarring or liver outcomes.
8 min read
SYNCHRONIZE-1: Survodutide Phase 3 Obesity Results Explained
Survodutide produced mean weight changes of -12.2% and -13.0% at 76 weeks versus -5.4% on placebo in its NEJM phase 3 trial. Here is what those numbers mean, why 16.6% also circulates, and what remains unknown.
8 min read
Orforglipron and the Heart: The Lancet Cardiovascular Safety Trial
ACHIEVE-4 found orforglipron non-inferior to insulin glargine for major cardiovascular events in high-risk adults with type 2 diabetes. What the result shows, what it leaves open, and how far it applies to people taking Foundayo for weight.
8 min read
GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)
A tracker of next-generation GLP-1 and incretin drugs: retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide and the approved oral pill orforglipron (Foundayo), with stage and peak reported weight loss.
7 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →Pricing Compare
Get started →Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →